Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Study Overview

• Status: Recruiting
• Conditions: Liver Cancer; Adjuvant Therapy; Sarcomatoid Carcinoma
• Intervention / Treatment: Procedure: postoperative adjuvant therapy

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Jiwei Huang Professor; Phone Number: +86 18980606725; Email: huangjiwei@wchscu.cn

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Recruiting
      • West China Hospital
      • Contact: Jiwei Huang Huang Professor; Phone Number: +86 18980606725; Email: huangjiwei@wchscu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.

Description

Inclusion Criteria:

1. patients who underwent liver resection
2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion Criteria:

1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
2. patients diagnosed with other specific types of sarcomas;
3. patients with concurrent other malignancies during the course of PHSC;
4. patients who were lost to follow-up or lacked essential clinical data.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy	Procedure: postoperative adjuvant therapy; Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease-free survival	Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.	From December 2018 to May 2023

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.	From December 2018 to May 2023

Collaborators and Investigators

• Sponsor: West China Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2025
• Primary Completion (Estimated): May 3, 2025
• Study Completion (Estimated): May 5, 2025

Study Registration Dates

• First Submitted: April 22, 2025
• First Submitted That Met QC Criteria: April 22, 2025
• First Posted (Actual): April 30, 2025

Study Record Updates

• Last Update Posted (Actual): April 30, 2025
• Last Update Submitted That Met QC Criteria: April 22, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Carcinoma
• Other Study ID Numbers: JHuang20231

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No